News|Articles|May 12, 2026

FDA Action Update, Week of May 4, 2026: Approvals, Extended Review, and Plans for NDA Filing

Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.

The FDA was busy early this month, during the week of May 4, 2026, making a number of decisions on potential new therapeutic agents, including granting a couple of approvals, and extending the review of a supplemental biologics license application (sBLA).